Activating ESR1 mutations in hormone-resistant metastatic breast cancer
暂无分享,去创建一个
Javed Siddiqui | Arul M Chinnaiyan | Pankaj Vats | Xuhong Cao | Rashmi Chugh | Moshe Talpaz | Kenneth J Pienta | Daniel F Hayes | K. Pienta | A. Chinnaiyan | J. Roberts | Shanker Kalyana-Sundaram | S. Tomlins | Xuhong Cao | D. Robinson | D. Hayes | J. Siddiqui | Pankaj Vats | M. Talpaz | J. Rae | S. Roychowdhury | Yi-Mi Wu | Fengyun Su | R. Lonigro | Rui Wang | L. Kunju | Yu Ning | C. V. Van Poznak | R. Chugh | A. Schott | J Scott Roberts | Yi-Mi Wu | Robert J Lonigro | Sameek Roychowdhury | Yu Ning | Fengyun Su | Rui Wang | Dan R Robinson | Scott A Tomlins | S. Kim | James M Rae | L. Hodges | Amy Gursky | C. Poznak | Lakshmi P Kunju | Anne F Schott | Shanker Kalyana-Sundaram | Lynda Hodges | Amy Gursky | Scott Y Kim | Catherine H Van Poznak | Scott Y. H. Kim | J. Roberts | Xuhong Cao
[1] Gang Shao,et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.
[2] Joshua M. Korn,et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.
[3] Nickolay A. Khazanov,et al. Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.
[4] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[5] P. Lønning,et al. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved , 2013, Endocrine-related cancer.
[6] Daniel F. Hayes,et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer , 2013 .
[7] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[8] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[9] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.
[10] Joshua F. McMichael,et al. Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.
[11] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[12] David R. Kelley,et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.
[13] Todd R. Golub,et al. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling , 2011, Oncogene.
[14] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[15] Arul M Chinnaiyan,et al. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. , 2011, Neoplasia.
[16] S. Salzberg,et al. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts , 2011, Genome Biology.
[17] Stephen L. Abrams,et al. Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy , 2011, Oncotarget.
[18] Ken Chen,et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. , 2011, JAMA.
[19] Jannik N. Andersen,et al. Cancer genomics: from discovery science to personalized medicine , 2011, Nature Medicine.
[20] Rachel Schiff,et al. Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.
[21] Jonathan W. Pillow,et al. POSTER PRESENTATION Open Access , 2013 .
[22] S. Gabriel,et al. Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.
[23] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[24] S. Fuqua,et al. Estrogen Receptor Mutations and Changes in Downstream Gene Expression and Signaling , 2010, Clinical Cancer Research.
[25] M. Ellis,et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. , 2009, JAMA.
[26] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[27] V. Jordan,et al. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. , 2008, Clinical breast cancer.
[28] R. Riggins,et al. Pathways to tamoxifen resistance. , 2007, Cancer letters.
[29] D. F. Skafar. Formation of a powerful capping motif corresponding to start of “helix 12” in agonist-bound estrogen receptor-α contributes to increased constitutive activity of the protein , 2007, Cell Biochemistry and Biophysics.
[30] E. Perez,et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] E. Ariazi,et al. Estrogen receptors as therapeutic targets in breast cancer. , 2006, Current topics in medicinal chemistry.
[32] A. Koide,et al. Mutation of Leu-536 in Human Estrogen Receptor-α Alters the Coupling between Ligand Binding, Transcription Activation, and Receptor Conformation* , 2003, Journal of Biological Chemistry.
[33] Hong Liu,et al. Modulation of Estrogen Receptor α Function and Stability by Tamoxifen and a Critical Amino Acid (Asp-538) in Helix 12* , 2003, The Journal of Biological Chemistry.
[34] D. McDonnell,et al. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. , 2002, Molecular endocrinology.
[35] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[36] David A. Agard,et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.
[37] K E Carlson,et al. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. , 1997, Biochemistry.
[38] P Chambon,et al. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. , 1997, Biochemical and biophysical research communications.
[39] B. Katzenellenbogen,et al. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. , 1996, Molecular endocrinology.
[40] M. Carcangiu. Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.
[41] C. Redmond,et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.